Pharmaceutical company Allergan plc (NYSE:AGN) reported on Tuesday the receipt of the US Food and Drug Administration (FDA) approval for Medicines360's Supplemental New Drug Application (sNDA) for the extension of the duration of use of LILETTA (levonorgestrel-releasing intrauterine system) in 52 mg for the prevention of pregnancy for up to five years.
This US FDA approval was based on a review of additional efficacy and safety data from the partnership's largest ongoing intrauterine system (IUS), known as intrauterine device (IUD), Phase 3 clinical trial in the US, ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS), with 1,751 US women receiving LILETTA.
The companies added that LILETTA proved to be more than 99% effective in preventing pregnancy for up to five years in a broad range of women as well as effective regardless of age, race, body mass index (BMI) or parity (whether or not the woman had given birth to at least one child).
According to the companies, LILETTA is a hormone-releasing system placed in a woman's uterus to prevent pregnancy for up to five years. The system should be replaced after five years if continued use is desired. it has introduced the single-handed inserter and, now, the extended duration of use for up to five years.
In the US, LILETTA is commercially available via Medicines360's unique mission-driven model as well as at a lower cost under the public health clinics' 340B Drug Pricing Programme.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data